New York, Feb 10, 2026, 10:54 a.m. EST — Regular session
- FMC shares jumped roughly 7% in morning trading, building on their recovery since Monday’s close.
- FMC shares have whipsawed since the company kicked off a strategic review—possibly leading to a sale—and cut its 2026 outlook.
- Citigroup stuck with its Neutral rating, though the analyst trimmed the price target to $14—leaving the bullish argument under some strain.
FMC Corp jumped roughly 7% in early Tuesday trading, reaching $16.46 after finishing Monday at $15.39. The crop-protection chemicals company’s shares moved within a range of $15.37 to $16.57 at the start of the session.
This bounce is notable. FMC, since its February reset, has become a quick-trigger event stock. The shares remain well under their 52-week peak of $44.78, so even minor changes in strategic review expectations are pushing the price around.
Price targets keep coming down. On Monday, Citigroup’s Patrick Cunningham held his Neutral call but trimmed the target to $14 from $16, GuruFocus reported.
Last week, FMC kicked things off by announcing its board would review “strategic options”—a potential sale included. It flagged 2026 as a softer year based on the midpoint of guidance. The company also detailed intentions to shave $1 billion off its debt, tapping asset sales and licensing, with CEO Pierre Brondeau emphasizing the push to “strengthen the balance sheet” as the board weighs its next move. FMC Corporation
The credit crowd is on edge, too. Moody’s knocked FMC’s senior unsecured ratings down to junk, pointing to the company’s ongoing strategic review as another layer of risk. “It increases event risk in 2026 and could push the rating lower,” Moody’s analyst John Rogers warned. Investing.com South Africa
Equity holders now face the key question: does the strategic process actually deliver something real — a deal, an asset sale, maybe a licensing package — or just drag out the clock? FMC called the review “preliminary,” adding that updates might not come outside of regular disclosures.
Conditions remain tough. FMC faces pricing pressure across segments of its portfolio and is navigating a post-patent phase for its Rynaxypyr insecticide ingredient, all while pushing to introduce new active ingredients.
Still, traders are watching for the risks: a failed deal, sluggish debt progress, or even stiffer competition could have shares following the company’s finances rather than its growth story. Another ratings downgrade? That would only make things worse.
Eyes are on fresh filings and possible board disclosures as the company wades through spring proxy season. This stretch can surface new information on strategy and governance that investors are eager to parse.
FMC will hold its annual shareholder meeting on April 28, this year, streaming it online. The company has pegged Feb. 27 as the record date for voting eligibility.
